Enovis (ENOV) Expected to Announce Quarterly Earnings on Thursday

Enovis (NYSE:ENOV) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $538.6120 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Monday, January 8th. The company reported $0.59 EPS for the quarter. The company had revenue of $383.81 million for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Trading Up 0.4%

Shares of ENOV opened at $31.52 on Wednesday. The stock’s 50-day moving average is $31.42 and its two-hundred day moving average is $31.53. The stock has a market cap of $1.80 billion, a PE ratio of -2.21 and a beta of 1.69. Enovis has a 12 month low of $25.47 and a 12 month high of $49.83. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15.

Insider Buying and Selling

In other Enovis news, CEO Damien Mcdonald bought 6,457 shares of the business’s stock in a transaction on Thursday, September 11th. The shares were purchased at an average price of $30.97 per share, with a total value of $199,973.29. Following the completion of the acquisition, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. The trade was a 6.71% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was acquired at an average cost of $29.71 per share, for a total transaction of $74,275.00. Following the acquisition, the chief financial officer directly owned 116,729 shares of the company’s stock, valued at $3,468,018.59. The trade was a 2.19% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 12,157 shares of company stock worth $374,760 over the last ninety days. 2.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Enovis

Large investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Enovis by 578.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,347 shares of the company’s stock valued at $136,000 after buying an additional 3,706 shares during the period. State of Wyoming boosted its stake in Enovis by 555,600.0% during the second quarter. State of Wyoming now owns 5,557 shares of the company’s stock valued at $174,000 after buying an additional 5,556 shares in the last quarter. Empowered Funds LLC boosted its stake in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after buying an additional 749 shares in the last quarter. Finally, Gabelli Funds LLC bought a new position in Enovis during the second quarter valued at about $289,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ENOV. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Wells Fargo & Company dropped their price objective on shares of Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. UBS Group dropped their price objective on shares of Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Evercore ISI dropped their price objective on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Finally, Canaccord Genuity Group dropped their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $51.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.